Efficacy of oral JAK1 or JAK1/2 inhibitor for treating refractory pruritus in dystrophic epidermolysis bullosa: A retrospective case series

医学 可视模拟标度 耐火材料(行星科学) 胃肠病学 内科学 临床终点 皮肤病科 外科 临床试验 天体生物学 物理
作者
Il Joo Kwon,Song‐Ee Kim,Soo‐Chan Kim,Sang Eun Lee
出处
期刊:Journal of Dermatology [Wiley]
卷期号:51 (3): 441-447 被引量:12
标识
DOI:10.1111/1346-8138.17079
摘要

Refractory pruritus is the most distressing, disease-related symptom in patients with dystrophic epidermolysis bullosa (DEB), inducing an itch-scratch-blister cycle. Chronic inflammation is a hallmark of DEB, thus upregulation of inflammatory cytokines and Janus kinase (JAK) signaling may play a role in DEB-related pruritus. We retrospectively reviewed the medical records of DEB patients with refractory pruritus who were treated with either baricitinib, a JAK1/2 inhibitor, or upadacitinib, a selective JAK1 inhibitor. Patients received baricitinib (4 mg) or upadacitinib (15 mg) once a day for 2-32 weeks. A total of 12 DEB patients (six recessive DEB and six dominant DEB) were included in this study. The mean±SD baseline pruritus visual analog scale (VAS) score was 7.5 ± 1.7. Upadacitinib or baricitinib treatment resulted in a rapid and sustained decrease in itch. Four out of 12 patients (33.3%) and seven out of 10 patients (70%) showed a decrease of at least 3 points in the pruritus VAS score from baseline at weeks 2 and 4, respectively. The mean percentage changes from baseline in pruritus VAS scores at weeks 2 and 4 were -42.9% and -52.7%, respectively. Subgroup analysis showed greater reductions in the pruritus VAS score in the baricitinib group (n = 5) compared to the upadacitinib group (n = 7), and in patients with epidermolysis bullosa pruriginosa (n = 3) compared to other subtypes of DEB (n = 9); however, these differences did not reach statistical significance. Three out of 10 (33.3%) patients showed at least a 2-point reduction in pain intensity from baseline at week 4. Eight out of 12 patients (66.7%) also showed a reduction in the number of new blisters, which correlated with a reduction in the pruritus score. No patient discontinued treatment because of serious adverse events. Our results suggest that JAK1 or JAK1/2 inhibitors could be a promising treatment option for DEB-related pruritus. Long-term safety should be assessed in future studies.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
2秒前
坦率的文龙完成签到,获得积分10
2秒前
小韩发布了新的文献求助10
4秒前
5秒前
6秒前
7秒前
sci_accept完成签到,获得积分10
9秒前
9秒前
10秒前
11秒前
112233445566发布了新的文献求助10
11秒前
YNYang完成签到,获得积分20
13秒前
13秒前
哈哈哈哈发布了新的文献求助10
13秒前
脑洞疼应助一只羊采纳,获得10
14秒前
wanci应助猫猫侠采纳,获得10
14秒前
sci_accept发布了新的文献求助30
15秒前
15秒前
丰富的乐瑶完成签到 ,获得积分10
15秒前
16秒前
廖述祥完成签到,获得积分10
16秒前
17秒前
仙笛童神发布了新的文献求助10
17秒前
18秒前
tanrui完成签到,获得积分10
19秒前
心灵美的石头完成签到,获得积分10
20秒前
未来可期发布了新的文献求助10
20秒前
陆家麟发布了新的文献求助10
21秒前
CodeCraft应助仙笛童神采纳,获得10
22秒前
科研小辣鸡完成签到,获得积分10
23秒前
yaro完成签到,获得积分10
23秒前
文静的柚子完成签到,获得积分10
24秒前
25秒前
27秒前
搜集达人应助LDD采纳,获得10
27秒前
Youngen完成签到,获得积分10
28秒前
若狂完成签到,获得积分10
28秒前
zxh656691发布了新的文献求助10
30秒前
WIL发布了新的文献求助10
32秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3967482
求助须知:如何正确求助?哪些是违规求助? 3512759
关于积分的说明 11164944
捐赠科研通 3247740
什么是DOI,文献DOI怎么找? 1794021
邀请新用户注册赠送积分活动 874785
科研通“疑难数据库(出版商)”最低求助积分说明 804517